Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Assets (2016 - 2025)

Historic Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $368.0 million.

  • Rocket Pharmaceuticals' Assets fell 651.66% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $368.0 million, marking a year-over-year decrease of 651.66%. This contributed to the annual value of $527.7 million for FY2024, which is 682.29% down from last year.
  • Rocket Pharmaceuticals' Assets amounted to $368.0 million in Q3 2025, which was down 651.66% from $421.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Assets ranged from a high of $598.8 million in Q3 2023 and a low of $368.0 million during Q3 2025
  • For the 5-year period, Rocket Pharmaceuticals' Assets averaged around $487.8 million, with its median value being $497.0 million (2021).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Assets skyrocketed by 5804.69% in 2021, and later tumbled by 3424.97% in 2024.
  • Rocket Pharmaceuticals' Assets (Quarter) stood at $497.0 million in 2021, then grew by 11.02% to $551.8 million in 2022, then grew by 2.63% to $566.3 million in 2023, then dropped by 6.82% to $527.7 million in 2024, then tumbled by 30.26% to $368.0 million in 2025.
  • Its Assets was $368.0 million in Q3 2025, compared to $421.0 million in Q2 2025 and $471.1 million in Q1 2025.